Boston, Massachusetts, United States
I am currently a graduate student pursuing a Master's degree in Bioengineering at Northeastern University. Through Northeastern's PlusOne program, I will be graduating in April 2026. In December 2025, I graduated cum laude from Northeastern University with a Bachelor's Degree in Bioengineering and a minor in Computer Science. With my concentration in Molecular, Cell, and Tissue Engineering, I was provided with learning opportunities inside and out of the lab. My co-op experiences at BioNTech and Vor Bio provided me with experience in research and development and in process development. Those co-ops provided me with an introduction to the biotechnology industry, specifically in cancer immunology. Immunology and oncology are both fields I'm passionate about, and I'm excited to see what projects the world has to offer!
- Partnered with Northeastern University Admissions to lead engaging, guided campus tours to prospective students and families - Presented to audiences of 250+ students and families, delivering an overview of the university’s offerings - Responded to emails from prospective students and applicants regarding the admissions process
BIOE2366 (Fall 2024, Fall 2025) - Supported instruction in both wet-lab and dry-lab modules for second-year Bioengineering students - Graded assignments and provided feedback to reinforce course concepts - Supervised lab sessions to ensure proper technique, safety compliance, and smooth workflow BIOE5710 (Spring 2026) - Supported a graduate-level systems and synthetic biology curriculum using E. coli as the model organism - Prepared lab space, equipment, and materials before each session - Assisted students by answering questions and guiding experimental troubleshooting
- Supported a multi-week in vivo CAR-T efficacy study of 65 mice by processing blood, spleen, and bone marrow to evaluate persistence and tumor clearance - Executed multicolor flow cytometry assays and interpreted results with FlowJo to characterize immune cell phenotypes and activation states - Conducted in vitro CAR-T cytotoxicity assays across multiple tumor cell lines, varying effector-to-target ratios and leveraging flow cytometry-based viability readouts to quantify functional potency - Quantified immune responses using multiplex cytokine profiling assays - Performed statistical analysis in Excel and data visualization in GraphPad Prism, generating figures to support data-driven conclusions
- Contributed to end-to-end process validation for a non-engineered autologous cell therapy, aimed at enriching and expanding neo-antigen specific T cells - Maintained sterile closed system T cell cultures ranging from 24-well to 5-liter G-Rex vessels under GMP-aligned workflows - Characterized antigen-specific T cells in healthy donor drug products using multicolor flow cytometry, metabolite analysis, and cytokine secretion assays - Isolated and cryopreserved PBMCs from leukopaks to support downstream cell therapy workflows - Utilized DoE to lead efforts to optimize neo-antigen MACS enrichment conditions - Applied scRNA sequencing to uncover T cell specific activation markers. Leveraged 10X and Illumina sequencing technology for both CITE surface protein expression and VDJ sequencing - Collaborated cross-functionally with members of PD, research, and MSAT - Communicated results to employees of all levels within cross-disciplinary teams